Next Article in Journal
Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects
Next Article in Special Issue
Studies on the Role of Compartmentalized Profiles of Cytokines in the Risk of Hepatocellular Carcinoma
Previous Article in Journal
Pathophysiological Insight into Fatty Acid-Binding Protein-4: Multifaced Roles in Reproduction, Pregnancy, and Offspring Health
Previous Article in Special Issue
Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 16
10.3390/ijms241612654
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies

by
Pei-Chin Lin
1,2,
Wan-Yi Hsu
1,
Po-Yi Lee
1,
Shih-Hsien Hsu
3,4,* and
Shyh-Shin Chiou
1,4,5,6,*
1
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan
2
School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
3
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
4
Center of Applied Genomics, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
5
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan
6
Division of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807378, Taiwan
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(16), 12654; https://doi.org/10.3390/ijms241612654
Submission received: 26 June 2023 / Revised: 2 August 2023 / Accepted: 7 August 2023 / Published: 10 August 2023
(This article belongs to the Special Issue Insights into Hepatocellular Carcinoma: From Pathophysiology to Novel Therapies)
Browse Figures
Review Reports Versions Notes

Abstract

:
Thalassemia is a heterogeneous congenital hemoglobinopathy common in the Mediterranean region, Middle East, Indian subcontinent, and Southeast Asia with increasing incidence in Northern Europe and North America due to immigration. Iron overloading is one of the major long-term complications in patients with thalassemia and can lead to organ damage and carcinogenesis. Hepatocellular carcinoma (HCC) is one of the most common malignancies in both transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). The incidence of HCC in patients with thalassemia has increased over time, as better chelation therapy confers a sufficiently long lifespan for the development of HCC. The mechanisms of iron-overloading-associated HCC development include the increased reactive oxygen species (ROS), inflammation cytokines, dysregulated hepcidin, and ferroportin metabolism. The treatment of HCC in patients with thalassemia was basically similar to those in general population. However, due to the younger age of HCC onset in thalassemia, regular surveillance for HCC development is mandatory in TDT and NTDT. Other supplemental therapies and experiences of novel treatments for HCC in the thalassemia population were also reviewed in this article.

1. Introduction

Thalassemia is a heterogeneous congenital hemoglobinopathy common in the Mediterranean region, Middle East, Indian subcontinent, and Southeast Asia [1,2,3,4]. Immigration has led to the gradual increase in the incidence of thalassemia in Northern Europe and North America [5,6]. Thalassemia can be classified based on defects in the globin chain, the α-globin chain or β-globin chain as α-thalassemia or β-thalassemia, respectively. Thalassemia is the most common monogenic disease worldwide, with approximately 1.5% of the population carrying the β-thalassemia allele and 5% carrying the α-thalassemia allele [5,7]. Clinical manifestations include anemia, jaundice, and iron overload, and the disease severity ranges from near-normal without complications to requiring lifelong transfusion support [3,6]. Patients with thalassemia requiring transfusion support are classified into transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) based on the frequency and regularity required. The lifespan will be less than 10–15 years without transfusions, and with transfusion therapy, it can be extended to approximately 50 years depending on the management of the iron overloading resulting from repeated red cell transfusions, which damage organ functions, especially the heart, liver, lung, pancreas, and pituitary glands [3,8,9]. Besides transfusions, increased dietary iron absorption is one of the major causes of liver iron overloading, typically in patients with NTDT [6,8]. Liver iron deposits lead to liver fibrosis, cirrhosis, and HCC [8]. The relationship between iron overload and HCC development is clear in that the incidence of HCC is much higher in patients with hereditary iron overload than in the general population [10]. A prospective study found that the incidence of HCC in patients with a beta-thalassemia major was approximately the same as the risk for HCC in the general population but with a significantly younger age at HCC diagnosis [11]. The incidence of HCC in patients with thalassemia has increased over time as better chelation therapy confers a sufficiently long lifespan for HCC development [12]. According to an analysis based on the Taiwan Health Insurance Longitudinal Database (1998–2010), patients with thalassemia had a significantly higher risk for abdominal cancer (aHR = 1.96, 95% CI 1.22–3.15) compared with the comparison group. Patients with thalassemia who received blood transfusions were 9.12 times more likely to develop abdominal cancer than those who did not receive blood transfusions [13]. Iron accumulation can also lead to various endocrinopathies, such as hypogonadism, impaired pancreatic excrete function, and hypothyroidism [14]. This review discusses the pathogenesis, molecular mechanisms, management, and perspectives of iron overloading associated with HCC in patients with thalassemia.

2. Risk Factors for HCC

2.1. Risk Factors for HCC in the General Population Focusing on Hepatitis Virus and Fatty Liver Disease

HCC is the sixth common cancer worldwide and the third leading cause of cancer death. The incidence in the general population varies widely in different world regions, with the highest in Mongolia (85.6 per 100,000) and the lowest in Sri Lanka (1.2 per 100,000) [15]. Before the advent of a vaccine against hepatitis B virus (HBV), the hepatitis B and C viruses (HCV) were the main risk factors for HCC over the past 40 years. The risk of HCC development in HBV carriers ranges from 9.6% in Hepatitis B surface antigen (HBsAg) positive patients to 60% in double positive (HBsAg + Hepatitis B e antigen (HBeAg)) patients [16]. In HCV-related cirrhosis patients, the risk of progression to HCC is estimated to be 2–6% each year [17].
Today, with a modern high-fat/sugar diet, sedentary lifestyle, and increasing alcohol consumption, alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are gradually being recognized as risk factors for HCC. Alcohol-related cirrhosis accounted for about 15–30% of HCC cases in one report [18]. The pathogenesis from ALD to HCC is complex; liver injury from the insult of reactive oxygen species (ROS) and acetaldehyde are contributing factors [16]. In chronic viral hepatitis patients, alcohol intake is associated with higher all-cause mortality and increases HCC development risk compared to the no alcohol intake group [19,20]. The global prevalence of NAFLD is estimated about 25% [21], and it is recognized now as the most common cause of cirrhosis and a growing risk factor for HCC [22]. Oxidative stress, chronic inflammation, and immune cell infiltration of fatty liver are all factors leading to HCC formation [23].

2.2. Risk Factors for HCC in the Thalassemia Group Focusing on Hepatitis Virus and Fatty Liver Disease

Because of life-long and frequent blood transfusions, thalassemic patients have a higher incidence of acquiring transfusion-transmitted viral infection, especially HBV and HCV. HBsAg positive was estimated in 0.3~5.7% of thalassemic patients [24]. Anti-HCV Ab was estimated 4.4~85.4% [25]. The actual incidence may vary widely because of differences in regional HBV/HCV prevalence.
As mentioned in the introduction, thalassemia major patients had impaired pancreatic function because of iron overload. The prevalence of diabetes mellitus (DM), mostly type 1, and impaired fasting sugar in thalassemic patients was about 6.54% and 17.21%, respectively [26]. NAFLD was deemed to be the result of insulin resistance and metabolic syndrome in the past, but now a high prevalence in type 1 DM patients is noted. Altered dynamic insulin pulsatile, altered insulin clearance, hyperglucagonemia, and hepatic glucagon resistance are parts of NAFLD pathogenesis in type 1 DM. These are slightly different from type 2 DM and metabolic syndrome patients [27]. Although there are no formal statistics of NAFLD prevalence in thalassemic patients, we inferred that owing to type 1 DM and iron overload (discussed next), the prevalence of NAFLD would be high in thalassemic patients.

2.3. Risk Factors for HCC in the Thalassemia Group Focusing on Iron Overload

In addition to the abovementioned risk factors, a special concern regarding HCC in the thalassemia group is iron overload resulting from lifelong blood transfusion and ineffective hematopoiesis. The NTDT group also suffers from iron overload to a lesser degree because of excessive hemolysis and chronic anemia. Iron overload is mainly due to blood transfusions and an excess of destroyed red blood cells (RBCs). To make things worse, patients with thalassemia generally have low hepcidin levels because of chronic anemia; so, their enterocytes still absorb iron greedily, even under an iron overload status [28].
Iron, an essential element for most species to live, is the most abundant metal on our planet [29]. Iron can easily gain or lose electrons by switching between the iron form (Fe2+) and the iron form (Fe3+). This characteristic enables iron to participate in the respiratory chain reaction, electron transfer, and signal transduction in cells and functions as an oxygen carrier in hemoglobin and myoglobin. The human body absorbs iron from food through enterocytes, which mostly go to the bone marrow for hemoglobin formation. RBCs are the largest iron reservoir in our body. After meeting the need for basic cellular function, surplus iron is mainly stored in the liver. Iron is such a precious metal for humans that we have not evolved the ability to excrete iron out of our body actively. Instead, we decrease our iron store reluctantly (passively) from blood loss. Menstruation is the only nontraumatic and natural way of losing blood [30,31]. To summarize, it is easy to accumulate iron in the body and almost impossible to excrete it, except during menstruation in women.
From the cellular level, various iron importers exist on the cell membrane, such as transferrin receptor protein 1 (TfR1), transferrin receptor 2 (TfR2), L-type calcium channel (LTCC), divalent metal transporter 1 (DMT1), zinc transporter 8 (ZIP8), and transient Receptor Potential Cation Channel Subfamily C Member 6 (TRPC6); however, ferroportin is the only exporter [30,31]. When thalassemia patients are forced to receive iron (ex. Blood transfusion), there is no way for them to excrete excessive iron. In the long-run, more and more iron participates in the body, mainly in the liver, and causes organ damage and affects cell function profoundly.
Iron overload is a risk factor for HCC. Hereditary hemochromatosis patients were more likely to have liver cancer compared to the general population [32,33]. It is estimated that iron-overloaded patients have a 10.6 times greater risk for HCC and even develop HCC before cirrhosis development [34]. Furthermore, hepatitis virus and iron can interact with each other and aggravate the liver cirrhosis process and HCC formation [35].

3. Pathogenesis of Viral Infection and NAFLD with HCC

The pathogenesis of HCC in patients with thalassemia is more complicated than in the general population. Figure 1 delineates the possible risk factors and associations between conditions specific to thalassemia and the development of HCC. The interactions of HBV/HCV, metabolic syndrome, and HCC are mentioned briefly in this section. The pathogenesis of iron-deposit-associated HCC is discussed separately in the next section.

3.1. HBV/HCV-Associated HCC

HBV and HCV contribute to HCC through different mechanisms. HBV is a DNA virus. It can integrate into the host genome and promote HCC formation by causing chromosome instability, promoting oncogene expression and activating cancer signaling pathways [36,37]. In an HCC patient with an HBV infection history, around 85% to 90% of the tumor tissue contains HBV DNA [38]. HBV infection also induces epigenetic dysregulation. It affects gene methylation and histone modification, activating oncogenes and silencing tumor suppressor genes. HBV is also capable of regulating microRNAs’ expression to advocate tumor metastasis, drug resistance, and proliferation. HBV infection also modulates our innate and adaptive immune system and transitions the liver microenvironment to a immunosuppressive status [36].
HCV is an RNA virus; so, it cannot integrate into the host genome consistently. Therefore, HCV infection does not have a strong oncogenic effect on HCC formation as HBV does, and it has also been less studied compared to HBV. HCV infection promotes HCC formation mainly by inducing epigenetic dysregulation, altering the cellular signaling pathway through viral RNA-encoded proteins [39].

3.2. NAFLD/NASH-Associated HCC

The process from NAFLD to HCC is deemed as a continuous one of steatosis [so-called non-alcoholic steatohepatitis (NASH)] with chronic inflammation to cirrhosis to carcinogenesis. About 2–13% of NAFLD-related cirrhosis patients have HCC development. However, around 8% of NAFLD-related HCC cases skip the cirrhosis stage and evolve to cancer directly [40,41]. Today, the process from NAFLD to NASH to cirrhosis is thought to be due to multiple factors, including chronic inflammation from free fatty acid and insulin resistance status, endotoxin and organokines from liver, altered immune cells, and the influence of gut-derived endotoxins [42,43]. These factors cause tumorigenesis as well.
Cirrhosis provides a microenvironment with a cancer-filled effect, where neoangiogenesis, fibrosis, and depressed immune surveillance offer senescent hepatocytes or primitive hepatocytes with mutated genes a chance to proliferate [44,45]. However, some studies have shown that cirrhosis restricts HCC development and can be an additional factor of immunosurveillance [46]. Thus, whether cirrhosis is a true risk factor for HCC is still under debate.

4. Pathogenesis of Iron Overload and HCC

4.1. Iron and Inflammation

When intrahepatic iron overflows, hepatocytes are also stimulated to differentiate into a proinflammatory state through excessive intracellular ferritin by enhancing the NF-κB expression pathway [47]. Prolonged activation of hepatocytes means they can differentiate into myofibroblasts and lead to neovascularization and extracellular matrix formation. Excessive iron molecules are not only deposited in but also injure hepatocytes. They also affect immune system function. Liver, as the largest reticuloendothelial system in the body, contains the largest population of macrophages (Kupffer cells). Macrophages, as scavengers in the body, phagocytize not only external harmful agents, such as bacteria, but also old dysfunctional cells, such as senescent RBCs and destroyed hepatocytes. Thus, they are prone to contain excessive amounts of iron, especially in patients with thalassemia. Excessive amounts of iron induce the macrophage to secrete proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12) [48]. Together, with the proinflammatory status of hepatocytes, complicated chronic inflammatory interaction ensues. Hepatic stellate cells, endothelial cells, and lymphocytes inside the liver all participate, and cirrhosis begins [49]. Cirrhosis provides an oncogenic environment for HCC formation [50,51,52]. A study of human liver tissue revealed that hepatocytes were polarized to myofibroblasts when the liver iron concentration (LIC) was >60 μmol/g. Cirrhosis ensues when the LIC is >250 μmol/g [53]. Fibrosis develops when the LIC is >400 μmol/g [54].

4.2. Iron and Reactive Oxygen Species (ROS)

When intracellular iron is excessive, these iron molecules participate in the Fenton reaction (Figure 2) and cause the accumulation of ROS [55]. Healthy cells can detoxify ROS through nonenzymatic and enzymatic antioxidants, such as glutathione, flavonoids, superoxide reductase, catalase, and glutathione peroxidase. If ROS formation exceeds the detoxifying ability of cells, excess ROS can cause genomic instability and reprogram cell metabolism toward carcinogenesis [56]. ROS induce hypoxia-inducible factor-1α expression and related angiogenic gene expression and thus promote angiogenesis [57]. ROS can also promote ERK/NF-kB pathway activation and facilitate tumor cell growth, migration, and deposition of extracellular matrix [58]. To summarize, ROS enhance tumor cell proliferation and survival.
Other than iron, HBV/HCV infection and NASH/NAFLD status provide many oxidative stresses to hepatocytes as well. In NAFLD, elevated mitochondrial fatty acid oxidation and impaired respiratory chain activity make ROS accumulate [59]. It was found that the HBV structural protein-HBx damaged the mitochondrial membrane potential by interacting with the outer membrane and affecting the respiratory complex; ROS production then increased [60]. With chronic HCV infection status, patients usually have a higher liver iron content and thus high ROS production [61]. Thus, in thalassemia patients, co-existence of hepatic viral infection and/or NAFLD with iron overload makes them vulnerable to hepatocarcinogenesis.

4.3. Hepcidin and Ferriportin

Hepcidin is a polypeptide hormone, isolated from plasma and urine samples with antimicrobial activities by two research groups in 2000 [62,63]. They showed that hepcidin was mainly produced by the liver, followed by the heart, brain, and lung [62]. Almost at the same time, Pigeon et al. tested the hepatic gene expressions in iron-overload mouse models and showed that hepcidin (HEPC), the gene encoding hepcidin, was overexpressed in iron overload hepatic cells. In the report, they also mapped the gene to the human chromosome 19 close to the upstream stimulatory factor-2 (USF2) gene [64]. Lipopolysaccharide, a main component of pathogenic molecules, acts on macrophages, including hepatic Kupffer cells, to induce interleukin-6 (IL-6) production, which in turn induces the overexpression of hepcidin mRNA in hepatocytes [65,66]. In summary, iron overloading, infection, and inflammation can induce hepatocyte hepcidin secretion, which leads to hypoferremia and the anemia of chronic inflammation. Anemia and hypoxia suppress hepcidin expression and result in tissue iron overload. Hepcidin regulates the absorption of dietary iron from the intestine, the release of recycled hemoglobin iron by macrophages, and the movement of stored iron from hepatocytes by blocking the iron transport in the intestinal epithelium, the placenta, and the macrophage [65]. Ferriportin, the only ion exporter in human cells, plays a critical role in hepcidin-regulated iron metabolism, where ferriportin–hepcidin binding leads to the internalization and degradation of ferriportin, and due to the decreased amounts of ferripotin, iron is trapped in hepatocytes, macrophages, and absorptive enterocytes. In consequence, cytoplasmic iron accumulates and reduces the cell uptake of iron. After plasma iron becomes depleted, mainly through hemoglobin synthesis by red cell precursors in the bone marrow, the hepcidin expression is suppressed and restores the iron hemostasis system [67].
As a key regulator of iron metabolism, hepcidin levels are influenced in the pathogenesis of anemia. Inefficient erythropoietic anemias, such as thalassemia, whose clinical manifestation is iron overload anemia, iron deficiency anemia, and congenital erythropoiesis, often have low or abnormal hepcidin relative to the anemia [28]. Kijima et al. examined hepcidin expression in cancerous and noncancerous liver tissues from 40 HCC patients and found that hepcidin mRNA expression was significantly suppressed in cancerous tissues compared to noncancerous liver tissues. It is noncancerous in HCC patients, regardless of the disease state such as tumor differentiation or the time to relapse. There was no significant difference in the mRNA expression of ferripotin and transferrin receptor 2 (TfR2) between cancerous and noncancer tissues [68]. On the other hand, Tan et al. found that hepcidin, TfR2, transferrin (Tf), ceruloplasmin (Cp), and iron regulatory protein 1 (IRP1), isolated in 24 HCC patients with chronic HBV infection, were downregulated compared to the adjacent tumor-free liver tissue and normal liver controls [69]. Similarly, Tseng et al. found that hepcidin, ceruloplasmin, transferrin, and transferrin-phosphorus receptor 2 were downregulated, transferrin receptor 1 was upregulated, and the hepcidin levels consistently correlated with hepatic iron stores in 50 HCC patients [70]. Kessler et al. showed that in cirrhotic tissues, hepcidin expression was lower compared to healthy liver samples in an HBV-related cohort as well as in HCV-infected patients, hepcidin expression was even lower in the HCC samples, and in their mouse models, they showed that hepcidin expression was decreased in early hepatocarcinogenesis as well as in a later stage of murine tumorigenesis [71]. Hepcidin also ameliorates liver fibrosis by inhibiting hepatic stellate cells (HSCs)’ activation, which facilitates liver fibrosis via the degradation of ferroportin in HSCs, increasing Akt phosphorylation and finally prohibiting TGFb1-inducible Smad3 phosphorylation [72].
The underlying mechanisms of suppressed hepcidin in HCC included the suppression of HAMP, TfR2, HJV, ALK2, and/or circular RNA circ_0004913, upregulations of matriptase-2 and/or GDF15, and the inactivation of RUNX3 and/or mutations in TP53 [73]. Hepcidin-induced ferriportin dysregulation has been reported to be associated with an increased risk of cancer, including HCC. FPN overexpression has been reported to be associated with a significant reduction in clonogenic ability, tumor regression, and liver metastasis in breast cancer cells [74,75]. The effects of hepcidin downregulation involve increased cancer proliferation via activation of the CDK1/STAT3 pathway and JAK/STAT pathway in a dependent manner [73,76].

5. Management

5.1. Management of Iron Overload

Once iron overloaded, patients with thalassemia should receive iron-chelation therapy. There are three iron-chelating drugs commercially available, deferoxamine (DFO) in subcutaneous or intravenous form, deferiprone (DFP) in oral form, and deferasirox (DFX) in oral form. All three drugs are useful for TDT patients, while DFX remains the only approved drug for NTDT patients. Selection of the iron chelator should be on the basis of the patient age, iron overload profile, presence or absence of comorbidities, patient preference and adherence, and side effects. For TDT patients with serum ferritin ≥ 1000 ng/mL or after transfusion of 10 units of packed red blood cells, iron-chelation therapy is recommended. For NTDT patients, iron-chelation therapy starts when serum ferritin ≥ 800 ng/mL or LIC ≥ 5 mg/g [9,77].
Iron overload and increased non-transferrin-bound iron lead to ROS production and subsequent oxidative damage. It is reasonable to assume that antioxidant therapy will be beneficial to iron overloaded thalassemia patients. Encouraging results from several randomized controlled trials have shown that natural antioxidants such as green tea and curcumin may be helpful; however, studies with a longer duration are needed to assess the long-term effects [78,79,80,81]. In 2021, according to the Thalassemia International Federation guidelines for the management of TDT, a diet rich in foods high in vitamin E, such as plant oils, eggs, nuts, and cereals, is recommended. To support the prolonged use of vitamin E supplements, further research is still needed [82].

5.2. Management of HCC

Because of limited data, the treatment of HCC in patients with thalassemia is primarily based on experience in non-thalassemic patients. Current treatment recommendations for HCC in the general population follow the Barcelona Clinic Liver Cancer (BCLC) staging system, in which patients with HCC are classified into five stages (stage 0: very early HCC, stage A: early HCC, stage B: intermediate HCC, stage C: advanced HCC, and stage D: terminal HCC), according to several prognostic variables, including tumor status, liver function (defined by Child-Pugh class), and performance status. In principle, patients with stage 0 and stage A should undergo surgical resection if they are candidates or local ablation. Liver transplantation is also a potentially curative treatment option for unresectable disease if eligible. For patients with advanced disease, systemic therapies will be applied first [83,84,85].
Patients with intermediate-stage HCC are highly heterogeneous in terms of tumor burden and liver function, and only a subset of this population could benefit from transarterial chemoembolization (TACE). To prolong overall survival, it is crucial to select the right patients for TACE or systemic therapy. In the 2019 Asia–Pacific Primary Liver Cancer Expert (APPLE) consensus statements, systemic targeted therapy was recommended as the initial treatment for intermediate-stage HCC patients with high tumor burden, who were unsuitable for TACE. The up-to-7 criteria is the most commonly used criteria to define a high tumor burden. A patient is beyond up-to-7 criteria if the sum of the tumor number and the diameter of the largest tumor (in centimeters) exceeds 7 [86]. In 2021, Huang et al. from Taiwan further classified intermediate-stage HCC patients by the newly proposed 7–11 criteria, showing a better performance in predicting radiologic response and survival after TACE [87].
The treatment modalities that have been reported and shown to be safe for HCC in thalassemia patients include surgical resection, radiofrequency ablation, microwave ablation, percutaneous ethanol injection, chemoembolization, radioembolization, sorafenib, and liver transplantation [11,24,88,89,90,91,92,93].
For a long time, liver transplantation has been refused to thalassemia patients mainly due to cardiac comorbidities. Based on the success stories reported in a series of cases, thalassemia per se should no longer be considered a contraindication to liver transplantation [24,93]. Liver transplantation is a potential treatment option for thalassemia patients once there are no significant comorbidities, such as severe pulmonary hypertension and overt heart disease [12,77,94,95].
In 2007, sorafenib became the first approved systemic therapy for HCC. Currently there are many approved therapies for advanced HCC, such as lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, pembrolizumab, the combination of atezolizumab and bevacizumab, the combination of nivolumab and ipilimumab, and the combination of tremelimumab and durvalumab [83,84,85,96,97,98]. Published data are lacking on use of these agents in patients with thalassemia and HCC. However, treatment of HCC in thalassemia patients should follow the same recommendations as in the non-thalassemic population. Novel immunotherapies, combination therapies, and chimeric antigen receptor (CAR)-T cell therapies are being tested for HCC, and thalassemia should not be regarded as a contraindication.
Intervention or modalities intending to block or reverse liver fibrosis are other possible treatment policies in patients with liver fibrosis before cancer transformation occurs. Hepatic stellate cells (HSCs)’ activation is a critical process in the development of liver fibrosis. HSCs reside in the space of Disse and are usually quiescent. Chronic inflammation of hepatocytes will activate HSCs, which then transform to myofibroblast-like cells. In the extracellular matrix (ECM) in fibrotic liver tissue, activated HSCs are the major components leading to excessive ECM deposition and scarring [99]. Chronic inflammation and liver fibrosis also create a microenvironment that can promote hepatocyte carcinogenesis by inducing genetic mutations and genomic instability in hepatocytes, influencing cell signaling pathways, angiogenesis, and immune responses. Activation of the TGF-β and Wnt/β-catenin signaling pathways and the aggregation of immune cells, such as tumor-associated macrophages can promote tumor growth and angiogenesis [100]. Significantly increased mitogenic cytokine IL6 and TNF levels were noted in advanced fibrosis, leading to a propensity towards cancer by regulating immune cells and the growth of tumor cells [101]. Hepatic fibrosis was previously recognized irreversible, but sequential liver biopsies in hepatitis B, hepatitis C, and NASH showed that removing the etiologies has a chance to reverse hepatic fibrosis [99]. Increased apoptosis or inactivation of HSCs is an important mechanism for the resolution of liver fibrosis [102]. Antifibrotic therapies that mediate its antifibrotic effects by hepatocyte protection, inhibition of HSC activation and fibrotic scar evolution or immune modulation may have therapeutic effects in liver fibrosis [102]. Clinical trials using Pan-caspase inhibitor, ASK1 inhibitor, Dual NOX1/4 inhibitor, FXR agonist, CBP/β-catenin small molecule inhibitor, Hsp47 siRNA delivering lipid nanoparticle, LOXL2 specific monoclonal antibody, CCR2/CCR5 inhibitor, and Inhibitor of galectin-3 were conducted for management of liver fibrosis with various outcomes [102]. Notably, Se, which is an important trace element metabolized in liver, can reduce oxidative stress, inhibit tumor growth, and prevent liver damage. The literature has shown that an increase in serum Se leads to an increase in the expression of selenoprotein P, and the inhibition of proinflammatory factors and its content in liver cancer cells is significantly reduced compared to healthy ones [103]. Selenium nanoparticles have shown good results in a variety of liver pathologies (inflammation, infectious, and oncological diseases) suggesting their hepatoprotective and anticancer effects both in vitro on liver cell culture and in vivo on animal models [103].

6. Prognosis

Worldwide, liver cancer is the sixth most common cancer and the third leading cause of cancer-related death. HCC accounts for 75–85% of liver cancer cases [15]. Thanks to advances in early diagnosis and treatment, survival rates for HCC have increased over the past three decades, with Surveillance Epidemiological Final Results reporting an overall increase in the 1-year survival rates from 18.2% to 51.2% [104]. The recently reported median survival of HCC in the general population was approximately 6.1–10.3 months. Survival differences were noted across etiologies of HCC due to differential screening and treatment practices, with more favorable survival in HBV-related HCC [95]. More studies have focused on HCC in patients with thalassemia; however, survival data for this population are still limited. In 2004, Borgna-Pignatti et al. from Italy reported that based on data collected from 52 centers, the median survival after HCC diagnosis was 3.5 months in patients with TDT and HCC [88]. Ten years later, in their update report, the median survival rose to 11.5 months [24]. In a previous study, the prognostic factor of survival in patients with TDT and HCC was investigated, and the only significant factor was Barcelona Clinic Liver Cancer staging [89].

7. Surveillance

In patients with thalassemia, iron overload and liver fibrosis must be monitored, and early-onset HCC detected. For the measurement of LIC, magnetic resonance imaging (MRI) T2* or R2* is a validated tool and has replaced invasive liver biopsy in current clinical practice. The current surveillance program suggests that the frequency of MRI should be based on the baseline LIC. If the baseline LIC is <3 mg/g, MRI is encouraged every 2 years; if 3–15 mg/g, MRI is recommended annually; and if >15 mg/g or the LIC or serum ferritin is rapidly increasing, MRI is advised every 6 months [105]. Transient elastography (e.g., Fibroscan®) is a reliable and accurate noninvasive test to assess liver fibrosis. According to current practice, transient elastography should be performed every 6–12 months if available [105,106].
Surveillance programs for HCC aim to detect cancer at early stages in patients at a high risk, for which potentially curative treatment options are indicated. The proposed mean doubling time of an HCC lesion is 117 days [107]. Current guidelines from the American Association for the Study of Liver Disease recommend biennial followups with abdominal ultrasonography, with or without alpha-fetoprotein (AFP). Considering cost-effectiveness and safety, multiphasic computed tomography (CT) and multiphasic MRI are reserved for diagnostic evaluation despite their high diagnostic efficiency [85]. In a previous meta-analysis, ultrasonography combined with AFP provided 63% sensitivity, higher than the 45% sensitivity with ultrasonography alone [108]. To improve the sensitivity for early detection of HCC, further studies may clarify the role of advanced imaging as a screening modality in selected cases.
Besides AFP, several new biomarkers and models such as the GALAD (gender, age, lectin-reactive AFP, AFP, des-gamma-carboxy prothrombin) score are being evaluated [109,110,111]. Novel biomarkers assays, such as cell-free DNA and microRNA, are also promising [110,111,112,113,114]. However, the optimistic results come from early-phase biomarker studies. New biomarkers need to be evaluated and validated in further studies before they can be incorporated into routine clinical practice.
HCC surveillance in thalassemia using abdominal ultrasonography, with or without AFP, has been proposed in the literature. The frequency of the majority of surveillance programs is every 6 months. However, differences exist regarding the target population. Some authors have suggested screening for HCC in all patients with thalassemia, while other authors have suggested screening in those with risk factors for HCC, including serum ferritin ≥ 1000 ng/mL, LIC ≥ 5 mg/g in NTDT, LIC ≥ 7 mg/g in TDT, concurrent HBV and/or HCV infection, and advanced cirrhosis [12,77,95]. In one review, the authors recommended screening in thalassemia patients aged > 30 or younger patients if a risk factor was present, given that the youngest patient reported to have thalassemia with HCC was 33 years old [106].

8. Conclusions

HCC is one of the most common cancers worldwide and the third leading cause of cancer death. In patients with thalassemia, repeated transfusion and increased gastrointestinal absorption of iron lead to liver iron deposit, which in turn result in ROS accumulation and proinflammatory pathway activation. Under the chronic inflammation status, cirrhosis gradually develops and becomes an oncogenic circumstance of hepatocytes. Therefore, HCC is one of the major complications in patients with thalassemia, and management for iron chelation, regular surveillance, and other supplementary treatments, like antioxidant therapy, were recommended. Treatment of HCC in patients with thalassemia is based on that in non-thalassemic patients, except that more consideration should be given to the cardiac and pulmonary conditions that are also influenced by iron overload. In the future, new treatment modalities, such as Luspatercept and gene therapy for thalassemia, can reduce the transfusion requirement and the iron deposit, and may be beneficial for preventing HCC development in patients with thalassemia.

Author Contributions

Conceptualization, P.-C.L., S.-S.C. and S.-H.H.; Investigation, P.-C.L., W.-Y.H. and P.-Y.L.; Writing—original draft preparation, P.-C.L., W.-Y.H. and P.-Y.L.; Writing—review and editing, S.-S.C. and S.-H.H.; Visualization, S.-H.H.; Supervision, S.-S.C. and S.-H.H. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by grants from the Kaohsiung Medical University Hospital, Kaohsiung, Taiwan (KMUH108-8M42 and KMUH111-1M36), Kaohsiung Medical University, Kaohsiung, Taiwan (DK-DK(A)112002) and the National Science and Technology Council, Taiwan: MOST110-2314-B-037-072-MY3, MOST111-2314-B-037-078, NSTC 112-2320-B-037-004, NSTC 112-2314-B-037-064.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Steinberg, M.H.; Forget, B.G.; Higgs, D.R.; Weatherall, D.J. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management; Cambridge University Press: Cambridge, UK, 2009. [Google Scholar]
  2. Weatherall, D.J. The inherited diseases of hemoglobin are an emerging global health burden. Blood J. Am. Soc. Hematol. 2010, 115, 4331–4336. [Google Scholar]
  3. Kattamis, A.; Kwiatkowski, J.L.; Aydinok, Y. Thalassaemia. Lancet 2022, 399, 2310–2324. [Google Scholar] [PubMed]
  4. Modell, B.; Darlison, M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull. World Health Organ. 2008, 86, 480–487. [Google Scholar]
  5. Kattamis, A.; Forni, G.L.; Aydinok, Y.; Viprakasit, V. Changing patterns in the epidemiology of β-thalassemia. Eur. J. Haematol. 2020, 105, 692–703. [Google Scholar] [PubMed]
  6. Taher, A.T.; Weatherall, D.J.; Cappellini, M.D. Thalassaemia. Lancet 2018, 391, 155–167. [Google Scholar] [PubMed]
  7. Piel, F.B.; Weatherall, D.J. The α-thalassemias. N. Engl. J. Med. 2014, 371, 1908–1916. [Google Scholar]
  8. Taher, A.T.; Saliba, A.N. Iron overload in thalassemia: Different organs at different rates. Hematol. Am. Soc. Hematol. Educ. Program Book 2017, 2017, 265–271. [Google Scholar]
  9. Taher, A.T.; Musallam, K.M.; Cappellini, M.D. β-Thalassemias. N. Engl. J. Med. 2021, 384, 727–743. [Google Scholar]
  10. Kowdley, K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127, S79–S86. [Google Scholar]
  11. Mancuso, A.; Sciarrino, E.; Concetta Renda, M.; Maggio, A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006, 30, 119–124. [Google Scholar]
  12. Moukhadder, H.M.; Halawi, R.; Cappellini, M.D.; Taher, A.T. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer 2017, 123, 751–758. [Google Scholar] [PubMed]
  13. Chung, W.-S.; Lin, C.-L.; Lin, C.-L.; Kao, C.-H. Thalassaemia and risk of cancer: A population-based cohort study. J. Epidemiol. Community Health 2015, 69, 1066–1070. [Google Scholar] [PubMed]
  14. Taher, A.; Musallam, K.; Cappellini, M.D. Guidelines for the Management of Non-Transfusion Dependent Thalassaemia (NTDT); TIF Publications: Nicosia, Cyprus, 2017. [Google Scholar]
  15. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [PubMed]
  16. Zhang, C.; Cheng, Y.; Zhang, S.; Fan, J.; Gao, Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022, 42, 2029–2041. [Google Scholar] [PubMed]
  17. Sangiovanni, A.; Del Ninno, E.; Fasani, P.; De Fazio, C.; Ronchi, G.; Romeo, R.; Morabito, A.; De Franchis, R.; Colombo, M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126, 1005–1014. [Google Scholar]
  18. Jepsen, P.; Ott, P.; Andersen, P.K.; Sørensen, H.T.; Vilstrup, H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: A Danish nationwide cohort study. Ann. Intern. Med. 2012, 156, 841–847. [Google Scholar]
  19. Lin, C.-W.; Lin, C.-C.; Mo, L.-R.; Chang, C.-Y.; Perng, D.-S.; Hsu, C.-C.; Lo, G.-H.; Chen, Y.-S.; Yen, Y.-C.; Hu, J.-T.; et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J. Hepatol. 2013, 58, 730–735. [Google Scholar]
  20. Sinn, D.H.; Kang, D.; Guallar, E.; Chang, Y.; Ryu, S.; Zhao, D.; Hong, Y.S.; Cho, J.; Gwak, G.-Y. Alcohol intake and mortality in patients with chronic viral hepatitis: A nationwide cohort study. Am. J. Gastroenterol. 2021, 116, 329–335. [Google Scholar]
  21. Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. [Google Scholar]
  22. Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [Google Scholar]
  23. Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2021, 7, 6. [Google Scholar] [PubMed]
  24. Borgna-Pignatti, C.; Garani, M.C.; Forni, G.L.; Cappellini, M.D.; Cassinerio, E.; Fidone, C.; Spadola, V.; Maggio, A.; Restivo Pantalone, G.; Piga, A.; et al. Hepatocellular carcinoma in thalassaemia: An update of the Italian Registry. Br. J. Haematol. 2014, 167, 121–126. [Google Scholar] [PubMed]
  25. Wonke, B.; Hoffbrand, A.; Brown, D.; Dusheiko, G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J. Clin. Pathol. 1990, 43, 638–640. [Google Scholar] [PubMed] [Green Version]
  26. He, L.-N.; Chen, W.; Yang, Y.; Xie, Y.-J.; Xiong, Z.-Y.; Chen, D.-Y.; Lu, D.; Liu, N.-Q.; Yang, Y.-H.; Sun, X.-F. Elevated prevalence of abnormal glucose metabolism and other endocrine disorders in patients with-thalassemia major: A meta-analysis. BioMed Res. Int. 2019, 2019, 6573497. [Google Scholar]
  27. Memaj, P.; Jornayvaz, F.R. Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology. Front. Endocrinol. 2022, 13, 1031633. [Google Scholar]
  28. Pagani, A.; Nai, A.; Silvestri, L.; Camaschella, C. Hepcidin and anemia: A tight relationship. Front. Physiol. 2019, 10, 1294. [Google Scholar]
  29. Frey, P.A.; Reed, G.H. The Ubiquity of Iron; ACS Publications: Washington, DC, USA, 2012. [Google Scholar]
  30. Muckenthaler, M.U.; Rivella, S.; Hentze, M.W.; Galy, B. A red carpet for iron metabolism. Cell 2017, 168, 344–361. [Google Scholar]
  31. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to tango: Regulation of Mammalian iron metabolism. Cell 2010, 142, 24–38. [Google Scholar]
  32. Grosse, S.D.; Gurrin, L.C.; Bertalli, N.A.; Allen, K.J. Clinical penetrance in hereditary hemochromatosis: Estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. Genet. Med. 2018, 20, 383–389. [Google Scholar]
  33. Atkins, J.L.; Pilling, L.C.; Masoli, J.A.; Kuo, C.-L.; Shearman, J.D.; Adams, P.C.; Melzer, D. Association of hemochromatosis HFE p. C282Y homozygosity with hepatic malignancy. JAMA 2020, 324, 2048–2057. [Google Scholar]
  34. Turlin, B.; Juguet, F.; Moirand, R.; Le Quilleuc, D.; Loréal, O.; Campion, J.-P.; Launois, B.; Ramée, M.-p.; Brissot, P.; Deugnier, Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995, 22, 446–450. [Google Scholar] [PubMed]
  35. Zanella, S.; Garani, M.C.; Borgna-Pignatti, C. Malignancies and thalassemia: A review of the literature. Ann. N. Y. Acad. Sci. 2016, 1368, 140–148. [Google Scholar] [PubMed]
  36. Jiang, Y.; Han, Q.; Zhao, H.; Zhang, J. The mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatocell. Carcinoma 2021, 8, 435–450. [Google Scholar]
  37. Simas, C.; Larson, H.J. Overcoming vaccine hesitancy in low-income and middle-income regions. Nat. Rev. Dis. Primers 2021, 7, 41. [Google Scholar]
  38. Xie, Y. Hepatitis B virus-associated hepatocellular carcinoma. In Infectious Agents Associated Cancers: Epidemiology and Molecular Biology; Springer: Singapore, 2017; pp. 11–21. [Google Scholar]
  39. Zhao, P.; Malik, S.; Xing, S. Epigenetic mechanisms involved in HCV-induced hepatocellular carcinoma (HCC). Front. Oncol. 2021, 11, 677926. [Google Scholar] [PubMed]
  40. Benhammou, J.N.; Lin, J.; Hussain, S.K.; El-Kabany, M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res. 2020, 6, 35. [Google Scholar]
  41. Said, A.; Ghufran, A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J. Clin. Oncol. 2017, 8, 429. [Google Scholar]
  42. Anstee, Q.M.; Reeves, H.L.; Kotsiliti, E.; Govaere, O.; Heikenwalder, M. From NASH to HCC: Current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 411–428. [Google Scholar]
  43. Tian, Z.; Xu, C.; Yang, P.; Lin, Z.; Wu, W.; Zhang, W.; Ding, J.; Ding, R.; Zhang, X.; Dou, K. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Front. Immunol. 2022, 13, 984728. [Google Scholar]
  44. Kim, H.; Lee, D.S.; An, T.H.; Park, H.-J.; Kim, W.K.; Bae, K.-H.; Oh, K.-J. Metabolic spectrum of liver failure in type 2 diabetes and obesity: From NAFLD to NASH to HCC. Int. J. Mol. Sci. 2021, 22, 4495. [Google Scholar]
  45. Kudo, M.; Finn, R.S.; Qin, S.; Han, K.-H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.-W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018, 391, 1163–1173. [Google Scholar]
  46. Garrido, A.; Djouder, N. Cirrhosis: A questioned risk factor for hepatocellular carcinoma. Trends Cancer 2021, 7, 29–36. [Google Scholar] [PubMed]
  47. Ruddell, R.G.; Hoang-Le, D.; Barwood, J.M.; Rutherford, P.S.; Piva, T.J.; Watters, D.J.; Santambrogio, P.; Arosio, P.; Ramm, G.A. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells. Hepatology 2009, 49, 887–900. [Google Scholar]
  48. Sindrilaru, A.; Peters, T.; Wieschalka, S.; Baican, C.; Baican, A.; Peter, H.; Hainzl, A.; Schatz, S.; Qi, Y.; Schlecht, A.; et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Investig. 2011, 121, 985–997. [Google Scholar] [PubMed] [Green Version]
  49. Ringelhan, M.; Pfister, D.; O’Connor, T.; Pikarsky, E.; Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 2018, 19, 222–232. [Google Scholar] [PubMed]
  50. Hoshida, Y.; Villanueva, A.; Sangiovanni, A.; Sole, M.; Hur, C.; Andersson, K.L.; Chung, R.T.; Gould, J.; Kojima, K.; Gupta, S.; et al. Prognostic gene expression signature for patients with hepatitis C–related early-stage cirrhosis. Gastroenterology 2013, 144, 1024–1030. [Google Scholar] [PubMed] [Green Version]
  51. Budhu, A.; Forgues, M.; Ye, Q.-H.; Jia, H.-L.; He, P.; Zanetti, K.A.; Kammula, U.S.; Chen, Y.; Qin, L.-X.; Tang, Z.-Y.; et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10, 99–111. [Google Scholar]
  52. Moeini, A.; Torrecilla, S.; Tovar, V.; Montironi, C.; Andreu-Oller, C.; Peix, J.; Higuera, M.; Pfister, D.; Ramadori, P.; Pinyol, R.; et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology 2019, 157, 1383–1397.e11. [Google Scholar] [PubMed] [Green Version]
  53. Adams, P.C. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am. J. Gastroenterol. 2001, 96, 567–569. [Google Scholar]
  54. Angelucci, E.; Muretto, P.; Nicolucci, A.; Baronciani, D.; Erer, B.; Gaziev, J.; Ripalti, M.; Sodani, P.; Tomassoni, S.; Visani, G.; et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood J. Am. Soc. Hematol. 2002, 100, 17–21. [Google Scholar]
  55. Dixon, S.J.; Stockwell, B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014, 10, 9–17. [Google Scholar] [PubMed]
  56. Moloney, J.N.; Cotter, T.G. Seminars in Cell & Developmental Biology; Elsevier: Amsterdam, The Netherlands, 2018; pp. 50–64. [Google Scholar]
  57. Choi, J.-E.; Kim, J.-H.; Song, N.-Y.; Suh, J.; Kim, D.-H.; Kim, S.-J.; Na, H.-K.; Nadas, J.; Dong, Z.; Cha, Y.-N.; et al. 15-Deoxy-Δ12, 14-prostaglandin J2 stabilizes hypoxia inducible factor-1α through induction of heme oxygenase-1 and direct modification ofprolyl-4-hydroxylase 2. Free Radic. Res. 2016, 50, 1140–1152. [Google Scholar] [PubMed]
  58. Cao, L.; Liu, J.; Zhang, L.; Xiao, X.; Li, W. Curcumin inhibits H2O2-induced invasion and migration of human pancreatic cancer via suppression of the ERK/NF-κB pathway. Oncol. Rep. 2016, 36, 2245–2251. [Google Scholar]
  59. Begriche, K.; Massart, J.; Robin, M.A.; Bonnet, F.; Fromenty, B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013, 58, 1497–1507. [Google Scholar] [CrossRef] [PubMed]
  60. Lee, H.R.; Cho, Y.; Lee, G.; You, D.; Yoo, Y.; Kim, Y. A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization. J. Viral Hepat. 2018, 25, 412–420. [Google Scholar]
  61. Lambrecht, R.W.; Sterling, R.K.; Naishadham, D.; Stoddard, A.M.; Rogers, T.; Morishima, C.; Morgan, T.R.; Bonkovsky, H.L.; Group, H.-C.T. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011, 140, 1490–1500.e3. [Google Scholar]
  62. Krause, A.; Neitz, S.; Mägert, H.J.; Schulz, A.; Forssmann, W.G.; Schulz-Knappe, P.; Adermann, K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000, 480, 147–150. [Google Scholar] [CrossRef] [Green Version]
  63. Park, C.H.; Valore, E.V.; Waring, A.J.; Ganz, T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001, 276, 7806–7810. [Google Scholar] [CrossRef] [Green Version]
  64. Pigeon, C.; Ilyin, G.; Courselaud, B.; Leroyer, P.; Turlin, B.; Brissot, P.; Loréal, O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 2001, 276, 7811–7819. [Google Scholar] [CrossRef] [Green Version]
  65. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102, 783–788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Nemeth, E.; Valore, E.V.; Territo, M.; Schiller, G.; Lichtenstein, A.; Ganz, T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101, 2461–2463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090–2093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Kijima, H.; Sawada, T.; Tomosugi, N.; Kubota, K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008, 8, 167. [Google Scholar] [CrossRef] [Green Version]
  69. Tan, M.G.K.; Kumarasinghe, M.P.; Wang, S.M.; Ooi, L.L.P.; Aw, S.E.; Hui, K.M. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp. Biol. Med. 2009, 234, 693–702. [Google Scholar] [CrossRef] [PubMed]
  70. Tseng, H.H.; Chang, J.G.; Hwang, Y.H.; Yeh, K.T.; Chen, Y.L.; Yu, H.S. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J. Cancer Res. Clin. Oncol. 2009, 135, 1413–1420. [Google Scholar] [CrossRef]
  71. Kessler, S.M.; Barghash, A.; Laggai, S.; Helms, V.; Kiemer, A.K. Hepatic hepcidin expression is decreased in cirrhosis and HCC. J. Hepatol. 2015, 62, 977–979. [Google Scholar] [CrossRef] [Green Version]
  72. Han, C.Y.; Koo, J.H.; Kim, S.H.; Gardenghi, S.; Rivella, S.; Strnad, P.; Hwang, S.J.; Kim, S.G. Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. Nat. Commun. 2016, 7, 13817. [Google Scholar] [CrossRef] [Green Version]
  73. Joachim, J.H.; Mehta, K.J. Hepcidin in hepatocellular carcinoma. Br. J. Cancer 2022, 127, 185–192. [Google Scholar] [CrossRef]
  74. Zhang, S.; Chen, Y.; Guo, W.; Yuan, L.; Zhang, D.; Xu, Y.; Nemeth, E.; Ganz, T.; Liu, S. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell. Signal. 2014, 26, 2539–2550. [Google Scholar] [CrossRef]
  75. Guo, W.; Zhang, S.; Chen, Y.; Zhang, D.; Yuan, L.; Cong, H.; Liu, S. An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim. Biophys. Sin. 2015, 47, 703–715. [Google Scholar] [CrossRef] [Green Version]
  76. Rah, B.; Farhat, N.M.; Hamad, M.; Muhammad, J.S. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: Therapeutic implications. Clin. Exp. Med. 2023. [Google Scholar] [CrossRef]
  77. Finianos, A.; Matar, C.F.; Taher, A. Hepatocellular carcinoma in β-thalassemia patients: Review of the literature with molecular insight into liver carcinogenesis. Int. J. Mol. Sci. 2018, 19, 4070. [Google Scholar] [PubMed] [Green Version]
  78. Hatairaktham, S.; Masaratana, P.; Hantaweepant, C.; Srisawat, C.; Sirivatanauksorn, V.; Siritanaratkul, N.; Panichkul, N.; Kalpravidh, R.W. Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients. Ann. Hematol. 2021, 100, 891–901. [Google Scholar] [CrossRef] [PubMed]
  79. Mohammadi, E.; Tamaddoni, A.; Qujeq, D.; Nasseri, E.; Zayeri, F.; Zand, H.; Gholami, M.; Mir, S.M. An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β-thalassemia major patients: A double-blind randomized controlled clinical trial. Phytother. Res. 2018, 32, 1828–1835. [Google Scholar]
  80. Al-Momen, H.; Hussein, H.K.; Al-Attar, Z.; Hussein, M.J. Green tea influence on iron overload in thalassemia intermedia patients: A randomized controlled trial. FResearch 2020, 9, 1136. [Google Scholar]
  81. Saeidnia, M.; Fazeli, P.; Erfani, M.; Nowrouzi-Sohrabi, P.; Tamaddon, G.; Karimi, M. The Effect of Curcumin on Iron Overload in Patients with Beta-Thalassemia Intermedia. Clin. Lab. 2022, 68, 210629. [Google Scholar]
  82. Farmakis, D.; Porter, J.; Taher, A.; Cappellini, M.D.; Angastiniotis, M.; Eleftheriou, A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. HemaSphere 2022, 6, e732. [Google Scholar]
  83. Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J.-L.; Schirmacher, P.; Vilgrain, V. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018, 69, 182–236. [Google Scholar]
  84. Llovet, J.; Kelley, R.; Villanueva, A. Hepatocellular carcinoma. Nat Rev Dis Primers. PubMed Artic. 2021, 7, 7. [Google Scholar]
  85. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750. [Google Scholar]
  86. Kudo, M.; Han, K.H.; Ye, S.L.; Zhou, J.; Huang, Y.H.; Lin, S.M.; Wang, C.K.; Ikeda, M.; Chan, S.L.; Choo, S.P.; et al. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020, 9, 245–260. [Google Scholar] [CrossRef] [PubMed]
  87. Hung, Y.W.; Lee, I.C.; Chi, C.T.; Lee, R.C.; Liu, C.A.; Chiu, N.C.; Hwang, H.E.; Chao, Y.; Hou, M.C.; Huang, Y.H. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer 2021, 10, 629–640. [Google Scholar] [CrossRef] [PubMed]
  88. Borgna-Pignatti, C.; Vergine, G.; Lombardo, T.; Cappellini, M.D.; Cianciulli, P.; Maggio, A.; Renda, D.; Lai, M.E.; Mandas, A.; Forni, G.; et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol. 2004, 124, 114–117. [Google Scholar] [CrossRef] [PubMed]
  89. Papadopoulos, N.; Kountouras, D.; Malagari, K.; Tampaki, M.; Theochari, M.; Koskinas, J. Characteristics and prognosis of hepatocellular carcinoma in multi-transfused patients with β-thalassemia. Experience of a single tertiary center. Mediterr. J. Hematol. 2020, 12, e2020013. [Google Scholar] [CrossRef]
  90. Filippiadis, D.; Velonakis, G.; Charalampopoulos, G.; Masala, S.; Kelekis, A.; Kelekis, N.J.C.; Radiology, I. Percutaneous Microwave Ablation for the Management of Hepatocellular Carcinoma in Transfusion-Dependent Beta-Thalassemia Patients. CardioVascular Interv. Radiol. 2022, 45, 709–711. [Google Scholar] [CrossRef]
  91. Ricchi, P.; Costantini, S.; Spasiano, A.; Cinque, P.; Esposito, S.; Filosa, A. Hepatocellular carcinoma in patients with thalassemia in the post-DAA era: Not a disappearing entity. Ann. Hematol. 2021, 100, 1907–1910. [Google Scholar]
  92. Maakaron, J.E.; Cappellini, M.D.; Graziadei, G.; Ayache, J.B.; Taher, A.T. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Ann. Hepatol. 2013, 12, 142–146. [Google Scholar]
  93. Restivo Pantalone, G.; Renda, D.; Valenza, F.; D’Amato, F.; Vitrano, A.; Cassarà, F.; Rigano, P.; Salvo, V.D.; Giangreco, A.; Bevacqua, E.; et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br. J. Haematol. 2010, 150, 245–247. [Google Scholar]
  94. Mancuso, A.; Perricone, G. Time to define a new strategy for management of hepatocellular carcinoma in thalassaemia? Br. J. Haematol. 2015, 168, 304–305. [Google Scholar] [CrossRef]
  95. Mangia, A.; Bellini, D.; Cillo, U.; Laghi, A.; Pelle, G.; Valori, V.M.; Caturelli, E. Hepatocellular carcinoma in adult thalassemia patients: An expert opinion based on current evidence. BMC Gastroenterol. 2020, 20, 251. [Google Scholar]
  96. Girardi, D.M.; Sousa, L.P.; Miranda, T.A.; Haum, F.N.; Pereira, G.C.; Pereira, A.A. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers 2023, 15, 1680. [Google Scholar] [PubMed]
  97. Koulouris, A.; Tsagkaris, C.; Spyrou, V.; Pappa, E.; Troullinou, A.; Nikolaou, M. Hepatocellular carcinoma: An overview of the changing landscape of treatment options. J. Hepatocell. Carcinoma 2021, 8, 387–401. [Google Scholar] [PubMed]
  98. Chan, S.L.; Wong, N.; Lam, W.J.; Kuang, M. Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives. J. Gastroenterol. Hepatol. 2022, 37, 1197–1206. [Google Scholar] [PubMed]
  99. Kisseleva, T.; Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 151–166. [Google Scholar] [CrossRef]
  100. O’Rourke, J.M.; Sagar, V.M.; Shah, T.; Shetty, S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J. Gastroenterol. 2018, 24, 4436–4447. [Google Scholar] [CrossRef]
  101. Park, E.J.; Lee, J.H.; Yu, G.-Y.; He, G.; Ali, S.R.; Holzer, R.G.; Österreicher, C.H.; Takahashi, H.; Karin, M. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell 2010, 140, 197–208. [Google Scholar] [CrossRef] [Green Version]
  102. Roehlen, N.; Crouchet, E.; Baumert, T.F. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020, 9, 875. [Google Scholar]
  103. Goltyaev, M.V.; Varlamova, E.G. The Role of Selenium Nanoparticles in the Treatment of Liver Pathologies of Various Natures. Int. J. Mol. Sci. 2023, 24, 10547. [Google Scholar] [CrossRef]
  104. Ding, J.; Wen, Z. Survival improvement and prognosis for hepatocellular carcinoma: Analysis of the SEER database. BMC Cancer 2021, 21, 1157. [Google Scholar]
  105. Taher, A.T.; Cappellini, M.D. How I manage medical complications of β-thalassemia in adults. Blood J. Am. Soc. Hematol. 2018, 132, 1781–1791. [Google Scholar]
  106. De Sanctis, V.; Soliman, A.T.; Daar, S.; Alansary, N.; Kattamis, A.; Skafida, M.; Galati, M.C.; Christou, S.; Campisi, S.; Messina, G.; et al. A concise review on the frequency, major risk factors and surveillance of hepatocellular carcinoma (HCC) in β-thalassemias: Past, present and future perspectives and the ICET-A experience. Mediterr. J. Hematol. Infect. Dis. 2020, 12, e2020006. [Google Scholar] [PubMed]
  107. Sheu, J.-C.; Sung, J.-L.; Chen, D.-S.; Yang, P.-M.; Lai, M.-Y.; Lee, C.-S.; Hsu, H.-C.; Chuang, C.-N.; Yang, P.-C.; Wang, T.-H.; et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985, 89, 259–266. [Google Scholar] [CrossRef] [PubMed]
  108. Tzartzeva, K.; Obi, J.; Rich, N.E.; Parikh, N.D.; Marrero, J.A.; Yopp, A.; Waljee, A.K.; Singal, A.G. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology 2018, 154, 1706–1718.e1. [Google Scholar]
  109. Johnson, P.J.; Pirrie, S.J.; Cox, T.F.; Berhane, S.; Teng, M.; Palmer, D.; Morse, J.; Hull, D.; Patman, G.; Kagebayashi, C.; et al. The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological BiomarkersDetection of Hepatocellular Carcinoma. Cancer Epidemiol. Biomark. Prev. 2014, 23, 144–153. [Google Scholar] [CrossRef] [Green Version]
  110. Schlosser, S.; Tümen, D.; Volz, B.; Neumeyer, K.; Egler, N.; Kunst, C.; Tews, H.C.; Schmid, S.; Kandulski, A.; Müller, M.; et al. HCC biomarkers–state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice. Front. Oncol. 2022, 12, 1016952. [Google Scholar]
  111. Shahini, E.; Pasculli, G.; Solimando, A.G.; Tiribelli, C.; Cozzolongo, R.; Giannelli, G. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. Int. J. Mol. Sci. 2023, 24, 4286. [Google Scholar] [PubMed]
  112. Foda, Z.H.; Annapragada, A.V.; Boyapati, K.; Bruhm, D.C.; Vulpescu, N.A.; Medina, J.E.; Mathios, D.; Cristiano, S.; Niknafs, N.; Luu, H.T.; et al. Detecting liver cancer using cell-free DNA fragmentomes. Cancer Discov. 2023, 13, 616–631. [Google Scholar] [CrossRef]
  113. Tran, N.H.; Kisiel, J.; Roberts, L.R. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep. 2021, 3, 100304. [Google Scholar]
  114. Zhang, X.; Wang, Z.; Tang, W.; Wang, X.; Liu, R.; Bao, H.; Chen, X.; Wei, Y.; Wu, S.; Bao, H.; et al. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology 2022, 76, 317–329. [Google Scholar] [CrossRef]
Ijms 24 12654 g001
Figure 1. Mechanisms of HCC development in thalassemia. a (in blue circle): Thalassemia is characterized by ineffective erythropoiesis and has low hepcidin levels and iron overload. b (in blue circle): Excessive iron from senescent RBC. c (in blue circle): Excessive iron deposit in endocrine organ results in pancreatic exocrine insufficiency which causing type 1 DM. d (in blue circle): high fat/fructose/glucose diet, and sedentary lifestyle. e (in blue circle): Excessive iron also deposits into liver. Blue arrow: Thalassemia causes premature destruction of RBC precursor and hemolysis owing to deformed RBC. Light pink arrow: Hemolysis, ineffective hematopoiesis, and chronic transfusions lead to premature death of RBC. Free iron is released accordingly. Bright pink arrow: NASH, iron overload and chronic hepatitis viral infection all accelerate the process of fibrosis to cirrhosis and worst but not always consequential, to HCC. Green arrow: NASH, iron overload and chronic hepatitis viral infection can aggravate each other and make the progress of liver fibrosis early-onset, more inevitable, and severe.
Figure 1. Mechanisms of HCC development in thalassemia. a (in blue circle): Thalassemia is characterized by ineffective erythropoiesis and has low hepcidin levels and iron overload. b (in blue circle): Excessive iron from senescent RBC. c (in blue circle): Excessive iron deposit in endocrine organ results in pancreatic exocrine insufficiency which causing type 1 DM. d (in blue circle): high fat/fructose/glucose diet, and sedentary lifestyle. e (in blue circle): Excessive iron also deposits into liver. Blue arrow: Thalassemia causes premature destruction of RBC precursor and hemolysis owing to deformed RBC. Light pink arrow: Hemolysis, ineffective hematopoiesis, and chronic transfusions lead to premature death of RBC. Free iron is released accordingly. Bright pink arrow: NASH, iron overload and chronic hepatitis viral infection all accelerate the process of fibrosis to cirrhosis and worst but not always consequential, to HCC. Green arrow: NASH, iron overload and chronic hepatitis viral infection can aggravate each other and make the progress of liver fibrosis early-onset, more inevitable, and severe.
Ijms 24 12654 g001
Ijms 24 12654 g002
Figure 2. Mechanism of ROS accumulation caused by the Fenton reaction. The reaction of peroxides with Fe2+ to yield soluble hydroxyl (HO•) or lipid alkoxy (RO•) radicals is referred to as the Fenton reaction.
Figure 2. Mechanism of ROS accumulation caused by the Fenton reaction. The reaction of peroxides with Fe2+ to yield soluble hydroxyl (HO•) or lipid alkoxy (RO•) radicals is referred to as the Fenton reaction.
Ijms 24 12654 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lin, P.-C.; Hsu, W.-Y.; Lee, P.-Y.; Hsu, S.-H.; Chiou, S.-S. Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies. Int. J. Mol. Sci. 2023, 24, 12654. https://doi.org/10.3390/ijms241612654

AMA Style

Lin P-C, Hsu W-Y, Lee P-Y, Hsu S-H, Chiou S-S. Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies. International Journal of Molecular Sciences. 2023; 24(16):12654. https://doi.org/10.3390/ijms241612654

Chicago/Turabian Style

Lin, Pei-Chin, Wan-Yi Hsu, Po-Yi Lee, Shih-Hsien Hsu, and Shyh-Shin Chiou. 2023. "Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies" International Journal of Molecular Sciences 24, no. 16: 12654. https://doi.org/10.3390/ijms241612654

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop